Literature DB >> 33843261

Adeno-Associated Virus-Mediated Overexpression of Interleukin-10 Affects the Immunomodulatory Properties of Equine Bone Marrow-Derived Mesenchymal Stem Cells.

Ashley D Cameron1, Kayla M Even1, Renata L Linardi1, Alix K Berglund2, Lauren V Schnabel2, Julie B Engiles1,3, Kyla F Ortved1.   

Abstract

Joint injury can cause posttraumatic inflammation, which if severe enough can lead to posttraumatic osteoarthritis (PTOA), a progressive and debilitating condition. Posttraumatic inflammation is characterized by an influx of T lymphocytes and upregulation of inflammatory cytokines and degradative enzymes by activated chondrocytes and synoviocytes. Intra-articular bone marrow-derived mesenchymal stem cell (BM-MSC) injection for the treatment of osteoarthritis (OA) has been of interest due to the immunomodulatory properties of these cells. Interleukin (IL)-10, a potent immunomodulatory cytokine, has also been investigated as an OA therapeutic. Therefore, the objective of this study was to evaluate the combinatorial effects of BM-MSCs and IL-10 in OA using a gene therapy approach. We hypothesized that BM-MSCs overexpressing IL-10 would have superior immunomodulatory effects leading to increased suppression of T cell proliferation and decreased production of proinflammatory cytokines, providing protection of the extracellular matrix (ECM) in a stimulated, co-culture OA model. Treatment groups included the following: untransduced BM-MSC, adeno-associated virus (AAV)-IL10-transduced BM-MSC, and AAV-null transduced BM-MSC, which were unstimulated or stimulated with IL-1β/tumor necrosis factor-α (TNF-α). T cell proliferation was significantly decreased by the presence of BM-MSCs, especially when these BM-MSCs were AAV transduced. There was no significant difference in T cell suppression when cells were cultured with AAV-IL10-transduced or AAV-null transduced BM-MSCs. AAV transduction itself was associated with decreased synthesis of IL-1β, IL-6, and TNF-α. Expression of IL-1β and MMP13 was downregulated in AAV-transduced BM-MSCs and MMP13 expression was downregulated in cartilage explants co-cultured with AAV-transduced BM-MSCs. Despite mitigation of some proinflammatory cascades, rescue of ECM loss, as determined by glycosaminoglycan quantification and histological evaluation, did not occur in either AAV-IL10-transduced or AAV-null transduced co-cultures. Although IL-10 overexpression may enhance BM-MSC-mediated T cell suppression, we did not observe significant modulation of inflammation-driven cartilage degradation in cultures containing AAV-IL10-transduced BM-MSCs. AAV transduction itself does appear to affect paracrine signaling by BM-MSCs, which warrants further investigation.

Entities:  

Keywords:  AAV; IL-10; PTOA; immunomodulation; mesenchymal stem cell; osteoarthritis

Mesh:

Substances:

Year:  2021        PMID: 33843261     DOI: 10.1089/hum.2020.319

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  4 in total

1.  The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review.

Authors:  E M van Helvoort; E van der Heijden; J A G van Roon; N Eijkelkamp; S C Mastbergen
Journal:  Cartilage       Date:  2022 Apr-Jun       Impact factor: 3.117

2.  Inhibition of experimental autoimmune uveitis by intravitreal AAV-Equine-IL10 gene therapy.

Authors:  Elizabeth Crabtree; Katy Uribe; Sara M Smith; Darby Roberts; Jacklyn H Salmon; Jacquelyn J Bower; Liujiang Song; Prabhakar Bastola; Matthew L Hirsch; Brian C Gilger
Journal:  PLoS One       Date:  2022-08-18       Impact factor: 3.752

Review 3.  Gene therapy approaches for equine osteoarthritis.

Authors:  Parvathy Thampi; R Jude Samulski; Joshua C Grieger; Jennifer N Phillips; C Wayne McIlwraith; Laurie R Goodrich
Journal:  Front Vet Sci       Date:  2022-09-28

Review 4.  Strategies to Convert Cells into Hyaline Cartilage: Magic Spells for Adult Stem Cells.

Authors:  Anastasiia D Kurenkova; Irina A Romanova; Pavel D Kibirskiy; Peter Timashev; Ekaterina V Medvedeva
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.